Renovaro Biosciences ( (RENB) ) has shared an update.
Renovaro Inc. appoints David Weinstein as the new CEO, bringing his vast experience in investment banking and biotechnology, having sourced over $300 million for small-cap healthcare companies. Alongside Weinstein, the company welcomes new board members Maurice van Tilburg, James McNulty, Douglas Calder, and Mark Collins, each bringing unique expertise to strengthen the leadership. This leadership reshuffle follows several key resignations, reflecting a strategic shift in the company’s direction, poised for innovation in the biotech and healthcare sectors.
See more data about RENB stock on TipRanks’ Stock Analysis page.
